title: Process evaluation for biopharmaceuticals: what is appropriate in process evaluation?
authors.affiliation: SmithKline Beecham Pharmaceuticals, King of Prussia, PA, USA.
authors.forename: A S
authors.initials: AS
authors.lastname: Lubiniecki
authors.forename: P R
authors.initials: PR
authors.lastname: McAllister
authors.forename: T M
authors.initials: TM
authors.lastname: Smith
authors.forename: P J
authors.initials: PJ
authors.lastname: Shadle
mesh_terms: D000818:Animals; D001688:Biological Products / Q000592:standards*; D016466:CHO Cells / Q000821:virology; D006224:Cricetinae; D004340:Drug Contamination / Q000517:prevention & control*; D049673:History, 20th Century; D006801:Humans; D015203:Reproducibility of Results; D012190:Retroviridae / Q000302:isolation & purification; D018570:Risk Assessment; D013242:Sterilization / Q000379:methods; D014765:Viral Vaccines / Q000009:adverse effects / Q000266:history*; D014771:Virion / Q000302:isolation & purification; D014777:Virus Diseases / Q000635:transmission*
chemical_list: D001688:Biological Products; D014765:Viral Vaccines